BRAF and melanoma: Additionally, in patients with BRAF V600-mutant melanoma, the triple combination of vemurafenib, cobimetinib, and XL888 demonstrated significant antitumor activity, including an ORR of 76%, median PFS of 7.6 months, and OS of 41.7 months; however, frequent dose adjustments were required [111].